Events/ Events/ Oncology PARP & DDR Inhibitors Summit 2021 jenna.warren@hansonwade.com DDR therapeutics, PARP, PARP inhibitors, Target Discovery, Translational Oncology Optimize PARP inhibitors in the clinic Share X PARP & DDR Inhibitors Summit 2021 https://pharmaphorum.com/events/parp-ddr-inhibitors-summit-2021/
News/ News/ Oncology AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment George Underwood AstraZeneca, Calquence, chronic lymphocytic leukaemia, CLL, Lynparza, Merck & Co, MSD, ovarian cancer, PARP 0 Comment AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share X AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment https://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
News/ News/ Oncology/ Top stories Merck and Pfizer stop third Bavencio ovarian cancer trial George Underwood Bavencio, immuno-oncology, immunotherapy, Merck, ovarian cancer, PARP, Pfizer 0 Comment Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced Share X Merck and Pfizer stop third Bavencio ovarian cancer trial https://pharmaphorum.com/news/merck-and-pfizer-stop-third-bavencio-ovarian-cancer-trial/
News/ News/ R&D/ Top stories GSK enters PARP space with TESARO acquisition George Underwood GSK, PARP, Tesaro 0 Comment GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its Share X GSK enters PARP space with TESARO acquisition https://pharmaphorum.com/news/gsk-enters-parp-space-with-tesaro-acquisition/